Tonix Pharmaceuticals to Present Real-World Data on Fibromyalgia Treatment at ISPOR 2026
Tonix Pharmaceuticals will present findings from a retrospective cohort study on fibromyalgia treatment patterns using U.S. claims data, offering insights into real-world usage following the launch of its newly approved drug TONMYA.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 that will highlight findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA in August 2025 and its subsequent U.S. commercial launch in November 2025. This data is expected to provide valuable information on treatment patterns and potentially underscore the unmet need that TONMYA aims to address.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in more than 15 years, and its approval marks a significant milestone for Tonix Pharmaceuticals. The company is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The real-world data to be presented at ISPOR 2026 could help healthcare providers and payers understand how fibromyalgia is currently managed and where TONMYA may fit into the treatment landscape.
The implications of this announcement are noteworthy for several reasons. First, fibromyalgia is a chronic condition that affects millions of people worldwide, and the lack of new treatment options over the past decade and a half has been a concern for patients and clinicians. The introduction of TONMYA offers a novel therapeutic approach, and real-world data can validate its potential impact outside of clinical trials. Second, the presentation at ISPOR, a leading conference for health economics and outcomes research, signals Tonix's commitment to demonstrating the value of its product through rigorous evidence. This could influence formulary decisions and reimbursement policies.
Beyond fibromyalgia, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Additionally, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For investors, the real-world data presentation could provide insights into the commercial traction of TONMYA and the broader market opportunity. The full press release is available at https://ibn.fm/A3668. More information about Tonix Pharmaceuticals can be found in the company's newsroom at https://ibn.fm/TNXP.